Yahoo Finance
Yahoo Finance Plus Alzheimer's Disease Therapeutics Market to record USD 3.99 Bn growth -- Driven by the availability, research, and development of novel biomarkers
NEW YORK, Sept. 28, 2022 /PRNewswire/ -- The global Alzheimer's disease therapeutics market size is expected to grow by USD 3.99 billion, accelerating at a CAGR of 8.76% between 2021 and 2026, according to the latest research report by Technavio. The report has considered various factors including the patient population, prevalence rate of Alzheimer's disease, revenue generated by vendors, and disposable income among others to estimate the size of the market. Download PDF Report Sample
The Alzheimer's disease therapeutics market is fragmented. The market has several approved therapeutics for the symptomatic treatment of Alzheimer's disease. The strong prevalence of the disease and the need for highly efficacious therapeutics are compelling several vendors to develop new vaccines. Besides, the strong pipeline of novel therapeutics is expected to pave the way for new entrants. Hence, the market is expected to witness the launch of various novel therapeutics and the entry of a few new players during the forecast period. This will intensify the competition in the market and encourage vendors to form strategic alliances to increase their product offerings and geographical reach.
Some of the key vendors operating in the market include the following:
AbbVie Inc.: The company offers Alzheimer's disease therapeutics products such as NAMENDA XR.
Aurobindo Pharma Ltd.: The company offers Alzheimer's disease therapeutics products such as Galantamine Tablets USP 4mg, 8mg, and 12mg.
Biogen Inc.: The company operates through one business segment and is involved in discovering, developing, and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
Eisai Co. Ltd.: The company offers Alzheimer's disease therapeutics products such as ADUHELM.
Eli Lilly and Co.: The company offers Alzheimer's disease therapeutics products such as TRAILBLAZER-ALZ.
Although the availability, research, and development of novel biomarkers will offer immense growth opportunities, the high cost of therapeutics development will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Get detailed insights into market behavior. Buy Report Now
Alzheimer's Disease Therapeutics Market 2022-2026: Segmentation Analysis
Alzheimer's Disease Therapeutics Market is segmented as below:
Drug Class
The market observed high demand for cholinesterase inhibitors from end-users in 2021. Factors such as substantial progress in understanding the basic neurobiology of Alzheimer's disease and the increased availability of new drugs such as cholinesterase inhibitors are driving the growth of the segment.
Geography
North America will dominate the growth of the market, occupying 37% of the global market share. The increasing awareness and the strong prevalence of Alzheimer's disease are driving the growth of the regional market. Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our Alzheimer's disease therapeutics market report covers the following areas:
Alzheimer's Disease Therapeutics Market 2022-2026: Vendor Analysis
We provide a detailed analysis of around 25 vendors operating in the Alzheimer's disease therapeutics market, including some of the dominant vendors. Backed with competitive intelligence and benchmarking, our research report on the Alzheimer's disease therapeutics market is designed to provide entry support, customer profile, and M&As as well as go-to-market strategy support.
Alzheimer's Disease Therapeutics Market 2022-2026: Key Highlights
CAGR of the market during the forecast period 2022-2026
Detailed information on factors that will assist Alzheimer's disease therapeutics market growth during the next five years
Estimation of the Alzheimer's disease therapeutics market size and its contribution to the parent market
Predictions on upcoming trends and changes in consumer behavior
The growth of the Alzheimer's disease therapeutics market
Analysis of the market's competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of Alzheimer's disease therapeutics market vendors
Related Reports:
Alzheimer's Disease Therapeutics Market Scope | |
Report Coverage | Details |
Page number | 120 |
Base year | 2021 |
Forecast period | 2022-2026 |
Growth momentum & CAGR | Accelerate at a CAGR of 8.76% |
Market growth 2022-2026 | USD 3.99 billion |
Market structure | Fragmented |
YoY growth (%) | 8.41 |
Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution | North America at 37% |
Key consumer countries | US, Canada, UK, Germany, Japan, and China |
Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
Companies profiled | AB Science SA, AbbVie Inc., AgeneBio Inc., Aurobindo Pharma Ltd., Biogen Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lupin Ltd., Neuronascent Inc., Novartis AG, Shanghai Green Valley Pharmaceuticals Co. Ltd., Spinogenix Inc., T3D Therapeutics Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Vivoryon Therapeutics AG |
Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table Of Contents:
1 Executive Summary
1.1 Market overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
4 Five Forces Analysis
4.1 Five forces summary
4.2 Bargaining power of buyers
4.3 Bargaining power of suppliers
4.4 Threat of new entrants
4.5 Threat of substitutes
4.6 Threat of rivalry
4.7 Market condition
5 Market Segmentation by Drug Class
5.1 Market segments
5.2 Comparison by Drug Class
5.3 Cholinesterase inhibitors - Market size and forecast 2021-2026
5.4 N-methyl-D-aspartate receptor antagonist - Market size and forecast 2021-2026
5.5 Other drug class - Market size and forecast 2021-2026
5.6 Market opportunity by Drug Class
6 Customer Landscape
6.1 Customer landscape overview
7 Geographic Landscape
7.1 Geographic segmentation
7.2 Geographic comparison
7.3 North America - Market size and forecast 2021-2026
7.4 Europe - Market size and forecast 2021-2026
7.5 Asia - Market size and forecast 2021-2026
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
7.7 US - Market size and forecast 2021-2026
7.8 Canada - Market size and forecast 2021-2026
7.9 UK - Market size and forecast 2021-2026
7.10 Germany - Market size and forecast 2021-2026
7.11 Japan - Market size and forecast 2021-2026
7.12 China - Market size and forecast 2021-2026
7.13 Market opportunity by geography
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
8.4 Market trends
9 Vendor Landscape
9.1 Overview
9.2 Vendor landscape
9.3 Landscape disruption
9.4 Industry risks
10 Vendor Analysis
10.1 Vendors covered
10.2 Market positioning of vendors
10.3 AbbVie Inc.
10.4 Aurobindo Pharma Ltd.
10.5 Eisai Co. Ltd.
10.6 Eli Lilly and Co.
10.7 H Lundbeck AS
10.8 Johnson and Johnson
10.9 Lupin Ltd.
10.10 Novartis AG
10.11 Teva Pharmaceutical Industries Ltd.
10.12 Viatris Inc.
11 Appendix
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
11.3 Currency conversion rates for US$
11.4 Research methodology
11.5 List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/alzheimers-disease-therapeutics-market-to-record-usd-3-99-bn-growth--driven-by-the-availability-research-and-development-of-novel-biomarkers-301634253.html
SOURCE Technavio
